Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Lenvatinib, and GEMOX in Biliary Tract Cancer
NCT05620498Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in intrahepatic cholangiocarcinoma (ICC), gallbladder cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on NCT05620498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620498.